Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 73

1.

A Systemic Review and Experts' Consensus for Long-acting Injectable Antipsychotics in Bipolar Disorder.

Chou YH, Chu PC, Wu SW, Lee JC, Lee YH, Sun IW, Chang CL, Huang CL, Liu IC, Tsai CF, Yen YC.

Clin Psychopharmacol Neurosci. 2015 Aug 31;13(2):121-8. doi: 10.9758/cpn.2015.13.2.121.

2.

Clarifying the role of pattern separation in schizophrenia: the role of recognition and visual discrimination deficits.

Martinelli C, Shergill SS.

Schizophr Res. 2015 Aug;166(1-3):328-33. doi: 10.1016/j.schres.2015.06.004. Epub 2015 Jun 25.

PMID:
26117156
3.

Failure to use corollary discharge to remap visual target locations is associated with psychotic symptom severity in schizophrenia.

Rösler L, Rolfs M, van der Stigchel S, Neggers SF, Cahn W, Kahn RS, Thakkar KN.

J Neurophysiol. 2015 Aug;114(2):1129-36. doi: 10.1152/jn.00155.2015. Epub 2015 Jun 24.

4.

Treatment adherence and insight in schizophrenia.

Bitter I, Fehér L, Tényi T, Czobor P.

Psychiatr Hung. 2015;30(1):18-26.

PMID:
25867885
5.

Recognition of patients who would benefit from LAI antipsychotic treatment: how to assess adherence.

Correll CU.

J Clin Psychiatry. 2014 Nov;75(11):e29. doi: 10.4088/JCP.13024tx3c. Review.

6.

California State Hospital Violence Assessment and Treatment (Cal-VAT) guideline.

Stahl SM, Morrissette DA, Cummings M, Azizian A, Bader S, Broderick C, Dardashti L, Delgado D, Meyer J, O'Day J, Proctor G, Rose B, Schur M, Schwartz E, Velasquez S, Warburton K.

CNS Spectr. 2014 Oct;19(5):449-65.

PMID:
27358935
7.

A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea.

Lee NY, Kim SH, Cho SJ, Chung YC, Jung IK, Kim CY, Kim DH, Lee DG, Lee YH, Lim WJ, Na YS, Shin SE, Woo JM, Yoon JS, Yoon BH, Ahn YM, Kim YS.

Int Clin Psychopharmacol. 2014 Sep;29(5):279-87. doi: 10.1097/YIC.0000000000000030.

PMID:
24583566
8.

Postmortem femoral blood concentrations of risperidone.

Linnet K, Johansen SS.

J Anal Toxicol. 2014 Jan-Feb;38(1):57-60. doi: 10.1093/jat/bkt096. Epub 2013 Dec 8.

PMID:
24324228
9.

Switching from oral risperidone to flexibly dosed oral paliperidone extended-release: core symptoms, satisfaction, and quality of life in patients with stable but symptomatic schizophrenia: the RISPALI study.

Gattaz WF, Campos JA, Lacerda AL, Henna E, Ruschel SI, Bressan RA, de Oliveira IR, Rocha FL, Grabowski HM, Sacomani E Jr, Louzã MR, Quevedo J, Elkis H, Zorzetto Filho D, Périco Cde A, Lawson FL, Appolinário JC.

Curr Med Res Opin. 2014 Apr;30(4):695-709. doi: 10.1185/03007995.2013.869201. Epub 2013 Dec 16.

PMID:
24289141
10.

Cluster analysis of cognitive deficits may mark heterogeneity in schizophrenia in terms of outcome and response to treatment.

Gilbert E, Mérette C, Jomphe V, Emond C, Rouleau N, Bouchard RH, Roy MA, Paccalet T, Maziade M.

Eur Arch Psychiatry Clin Neurosci. 2014 Jun;264(4):333-43. doi: 10.1007/s00406-013-0463-7. Epub 2013 Oct 31.

11.
12.

Subjectivity and schizophrenia: another look at incomprehensibility and treatment nonadherence.

Parnas J, Henriksen MG.

Psychopathology. 2013;46(5):320-9. doi: 10.1159/000351837. Epub 2013 Jul 11.

PMID:
23860468
13.

Safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazole.

Potkin SG, Raoufinia A, Mallikaarjun S, Bricmont P, Peters-Strickland T, Kasper W, Baker RA, Eramo A, Sanchez R, McQuade R.

Curr Med Res Opin. 2013 Oct;29(10):1241-51. doi: 10.1185/03007995.2013.821973. Epub 2013 Jul 25.

PMID:
23822566
14.

Reintroduction of clozapine after perforation of the large intestine--a case report and review of the literature.

Ikai S, Suzuki T, Uchida H, Mimura M, Fujii Y.

Ann Pharmacother. 2013 Jul-Aug;47(7-8):e31. doi: 10.1345/aph.1S117. Epub 2013 Jun 11. Review.

PMID:
23757383
15.

Publication bias, with a focus on psychiatry: causes and solutions.

Turner EH.

CNS Drugs. 2013 Jun;27(6):457-68. doi: 10.1007/s40263-013-0067-9. Review.

PMID:
23696308
16.

Dopaminergic modulation of probabilistic reasoning and overconfidence in errors: a double-blind study.

Andreou C, Moritz S, Veith K, Veckenstedt R, Naber D.

Schizophr Bull. 2014 May;40(3):558-65. doi: 10.1093/schbul/sbt064. Epub 2013 May 9.

17.

Clinician perceptions, expectations, and management of negative symptoms in schizophrenia.

Marder SR.

J Clin Psychiatry. 2013 Jan;74(1):e01. doi: 10.4088/JCP.12045tx4c.

18.

Factors related to different reasons for antipsychotic drug discontinuation in the treatment of schizophrenia: a naturalistic 18-month follow-up study.

Vita A, Barlati S, Deste G, Corsini P, De Peri L, Sacchetti E.

Psychiatry Res. 2012 Dec 30;200(2-3):96-101. doi: 10.1016/j.psychres.2012.07.006. Epub 2012 Aug 1.

PMID:
22858250
19.

Aberrant sense of agency in patients with schizophrenia: forward and backward over-attribution of temporal causality during intentional action.

Maeda T, Kato M, Muramatsu T, Iwashita S, Mimura M, Kashima H.

Psychiatry Res. 2012 Jun 30;198(1):1-6. doi: 10.1016/j.psychres.2011.10.021. Epub 2012 Feb 27.

PMID:
22374553
20.

The low frequency of reported sexual dysfunction in Asian patients with schizophrenia (2001-2009): low occurrence or ignored side effect?

Xiang YT, Wang CY, Si TM, Lee EH, He YL, Ungvari GS, Chiu HF, Yang SY, Chong MY, Tan CH, Kua EH, Fujii S, Sim K, Yong MK, Trivedi JK, Chung EK, Udomratn P, Chee KY, Sartorius N, Shinfuku N.

Hum Psychopharmacol. 2011 Jun-Jul;26(4-5):352-7. doi: 10.1002/hup.1213. Epub 2011 Jul 12.

PMID:
21751252
Items per page

Supplemental Content

Loading ...
Write to the Help Desk